Brief: Vanda Announces Submission Of Biologics License Application To The FDA For Imsidolimab For The Treatment Of Generalized Pustular Psoriasis
15/12/2025 12:21
Dec 15 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O : VANDA ANNOUNCES SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO THE FDA FOR IMSIDOLIMAB FOR THE TREATMENT OF GENERALIZED PUSTULAR PSORIASIS VANDA PHARMACEUTICALS: PRIORITY REVIEW WOULD ESTABLISH 6-MONTH REVIEW CYCLE, POTENTIAL IMSIDOLIMAB FDA APPROVAL FOR GPP TREATMENT AS EARLY AS MID-2026 Source text: ID:nPn1J0jnCa Further company coverage: VNDA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AnaptysBio
See all newsU.S. RESEARCH ROUNDUP- Applied Materials, NVIDIA, Thermo Fisher Scientific
AnaptysBio's Q1 collaboration revenue falls, net loss widens
Brief: AnaptysBio Q1 Net Income USD -52.884 Million
Brief: Anaptys Appoints Chris Murphy As Chief Financial Officer And Owen Hughes To Board Of Directors
Brief: GSK Says Unit Tesaro's Claim For Declaratory Judgment Against Anaptysbio Unchanged